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CHAPTER 4
Synthesis of Modified Oligonucleotides
and Conjugates
INTRODUCTION
T he genetic information encoded in either genomic DNA or transcribed mRNAshas become an enticing target for chemical modifications and potential therapeutic
indications. Specifically, the search for methods that selectively prevent expression of
unwanted genes has been actively pursued for more than a decade. Theoretically, it is
possible to exploit the selective Watson-Crick hydrogen bond formation between comple-
mentary nucleic acid strands to control gene expression either by preventing transcription
of genomic DNA (an antigene strategy) or by interfering with the translation of mRNAs
(an antisense strategy) to gene products. With the advent of rapid and efficient methods
for automated synthesis of oligonucleotides, it has indeed been possible to prepare modi-
fied oligonucleotides complementary to specific nucleotide sequences of mRNA targets.
As a consequence of binding, and on the basis of particular cellular mechanisms, these
oligonucleotides can disrupt the flow of genetic information from transcribed mRNAs
to proteins. Thus, gene expression can be controlled at the mRNA level by modified
oligonucleotides, and this antisense strategy has led, over the years, to the development
of therapeutic oligonucleotides against cancer and various infectious diseases in humans.
In this context, UNIT 4.1 reports recent advances in the application of oligonucleotides as
drug candidates, describes the relationship between oligonucleotide modifications and
their therapeutic profiles, and provides general guidelines for enhancing oligonucleotide
drug properties.
Along similar lines, modern methods for the chemical synthesis of oligonucleotides
have facilitated the covalent attachment of reporter and conjugate groups to DNA and
RNA. Such modifications generate properties not normally present in native DNA or
RNA oligonucleotides. For example, addition of a conjugate group to an oligonucleotide
can be used to alter its solubility, charge, binding affinity, spectroscopic properties, and
function. Furthermore, oligonucleotide conjugates can provide structural information
on the nature of specific nucleic acid complexes such as protein-DNA(RNA) or ligand-
DNA(RNA) complexes. Unlike enzymatic methods, chemical methods for the incorpora-
tion of modified nucleosides into oligonucleotides permit a precise control over the type,
number, and placement of the reporter and conjugate groups within the sequence of inter-
est. Typically, fluorescent markers, intercalators, cross-linkers, and DNA/RNA cleaving
agents are added either to the 5′ or 3′ terminus of oligonucleotides, or inserted anywhere
within an oligonucleotide sequence. These oligonucleotide conjugates can then be specif-
ically dedicated to diagnostic or therapeutic applications. UNIT 4.2 presents an overview
of the methods employed for the attachment of reporter and conjugate groups to the 5′
terminus of oligonucleotides. The unit lists several reporter and conjugate groups that
can be directly incorporated into oligonucleotides mainly via ligand phosphoramidite or
H-phosphonate derivatives. This knowledge is reduced to practice in UNIT 4.3, which de-
lineates step-by-step protocols for the synthesis of intercalating and photo-cross-linking
ligand phosphoramidites as well as their addition to the 5′ terminus of oligonucleotides.
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Reporter and conjugate groups are, however, not always stable to the conditions used dur-
ing either oligonucleotide synthesis or the subsequent deprotection steps. Consequently,
the incorporation of these groups into oligonucleotides must be accomplished according
to an “indirect” approach. This method involves functionalization of the 5′ terminus of
oligonucleotides, mostly with nucleophilic groups. Although the indirect approach to the
preparation of oligonucleotide conjugates is extensively reviewed in UNIT 4.2, procedures
for the modification of oligonucleotides at the 5′ terminus are outlined in UNIT 4.9. Follow-
ing deprotection and purification, the functionalized oligonucleotides are then conjugated
to selected electrophilic reporter or conjugate groups. Methods describing the incorpora-
tion of functional groups into ligands are reported in UNIT 4.8, and methods for conjugation
of these ligands to the 5′-functionalized oligonucleotides are described in UNIT 4.10.
An attractive method for the preparation of oligonucleotide conjugates consists of func-
tionalizing the 5′-terminus of solid-phase-bound oligonucleotides with a diene phospho-
ramidite derivative followed by conjugation of the deprotected oligonucleotides with
selected dienophile reporter groups via a Diels-Alder cycloaddition reaction. The details
of this convenient conjugation method are provided in UNIT 4.18. For similar applications,
a facile and efficient 5′-iodination of solid-phase-linked oligonucleotides is presented
in UNIT 4.19. 5′-Iodo oligonucleotides allow conjugation with small molecules or macro-
molecules having a strongly nucleophilic group. While the functionalization of oligonu-
cleotides at either the 5′- or 3′-terminus is invaluable in the preparation of oligonucleotide
conjugates, the incorporation of uridine 2′-carbamates into oligonucleotides nicely com-
plements these methods for direct or indirect attachment of various ligands to DNA or
RNA. This versatile method is carefully detailed in UNIT 4.21.
The purification of synthetic oligonucleotides from a mixture of shorter sequences is
always a concern. Thus, purification methods that can easily provide oligonucleotides
of high purity are of great value. UNIT 4.20 highlights a reversible biotinylation of the
5′-terminus of oligonucleotides, which allows simple and highly effective affinity purifi-
cation of these biomolecules.
This chapter is also intended to include overviews and step-by-step protocols address-
ing the attachment of reporter and conjugate groups to the nucleobase, the 3′ terminus,
and the carbohydrate portion of oligonucleotides for diagnostic applications. In this re-
gard, UNIT 4.5 surveys a number of conjugation methods for oligonucleotides displaying
various 3′ functional groups, and UNIT 4.6 describes the step-by-step preparation of 3′-
aminoalkyl-ated or 3′-mercaptoalkylated oligonucleotides, and their respective conjuga-
tion to fluorescent reporter groups. Other protocols describing the preparation of oligonu-
cleotides with modified nucleobases, sugars, and internucleotide linkages for potential
therapeutic applications will also be incorporated into this chapter to provide a compre-
hensive coverage of these cutting edge technologies. In this context, UNIT 4.4 delineates
the solid-phase synthesis of chimeric 2-5A-DNA oligonucleotide conjugates along with
the preparation of the phosphoramidite monomers used for such synthesis. In addition,
the synthesis and purification of oligonucleotides composed of N3′→P5′ phosphorami-
date and either phosphodiester or phosphorothioate linkages, as presented in UNIT 4.7, is
a relevant example of such protocols. UNIT 4.11 provides manual and automated methods
for the synthesis of peptide nucleic acids (PNAs), whereas UNIT 4.12 details the synthesis
of locked nucleic acids (LNAs). These modified nucleic acids exhibit high affinity for
complementary RNA and DNA strands, and are thus amenable to a wide range of biomed-
ical applications. In this regard, a procedure for the incorporation of LNAs into cells is
reported in UNIT 4.13. The conjugation of peptides to oligonucleotides to generate nucle-
opeptides is the focus of intense scrutiny given the reported abilities of these conjugates
at enhancing intracellular delivery of therapeutic oligonucleotides. However, the prepa-
ration of peptide-oligonucleotide conjugates is challenging. An inspiring method for theIntroduction
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stepwise solid-phase synthesis of nucleopeptides is delineated in UNIT 4.22, thus making
these bioconjugates more available for further cell delivery studies.
Synthetic nucleic acids containing vicinal 2′,5′- and 3′,5′-phosphodiester linkages have
been useful to investigations related to pre-mRNA splicing events and to studies assessing
the specificity of RNA lariat debranching enzymes. These branched nucleic acids may
also find applications in the development of biosensors and diagnostics, or may serve as
“molecular anchors” in the formation of triplex and tetraplex structures. Two synthetic
strategies for the preparation of branched oligonucleotides are outlined and developed in
UNIT 4.14.
Transfer RNAs (tRNAs) incorporate a variety of modified nucleobases, which are known
to affect the biological activity of tRNAs through structural changes. To better understand
the role of these modified nucleobases, UNIT 4.23 reports on the synthesis of ribonucleo-
side phosphoramidites functionalized with either 6-methylthio purine or 2-methylthio-6-
chloro purine for incorporation into relatively short RNA oligonucleotide models. Fol-
lowing oligonucleotide synthesis using these phosphoramidites, the modified nucleobases
are chemically converted to a number of native tRNA nucleobase modifications to further
studies in this research area.
Modified nucleic acids such as 2′-deoxy-2′-fluoro-β-D-oligoarabinonucleotides are
unique in that they form more stable duplex structures with RNA complements than
identical unmodified DNA:RNA duplexes. In addition, the modified heteroduplexes are
substrates for RNase H, an enzyme viewed by many as the major effector of antisense
activity. Thus, given the promising antisense properties of 2′-fluoroarabinonucleic acids,
methods for the synthesis of 2′-deoxy-2′-fluoro-β-D-arabinonucleoside phosphoramidites
and their use in the automated synthesis of 2′-fluoroarabinonucleotides are included in
UNIT 4.15.
Substitution of native nucleobases with 7-deazapurines (pyrrolo[2,3-d]pyrimidines)
functionalized with halogeno or alkynyl groups at C7 has been shown to stabilize DNA
duplexes. This serves as a creative example in the design of therapeutic oligonucleotides
with high-affinity binding for complementary nucleic acid targets. The preparation of
these modified DNA oligonucleotides using phosphoramidite monomers is described in
UNIT 4.25. Synthesis of the pyrrolo[2,3-d]pyrimidine 2′-deoxyribonucleoside precursors
will be provided in UNIT 1.10 in an upcoming supplement.
An additional class of oligonucleotides for potential therapeutic applications includes
phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotide analogs. These
modified oligonucleotides are highly resilient to nucleases, and yet they are anionic, water
soluble, and form hybrids with both native DNA and RNA complementary sequences. It
is noteworthy that both oligonucleotide analogs stimulate RNase H–mediated hydrolysis
of the complementary RNA strand of each DNA:RNA hybrid. UNIT 4.24 presents the
detailed preparation of the deoxyribonucleoside phosphoramidites required for solid-
phase synthesis of phosphonoacetate and thiophosphonoacetate oligonucleotides, along
with methods used for purification and characterization of these oligonucleotide analogs.
Phosphorothioated oligonucleotides have also found therapeutic applications in antisense
settings. Such modified oligonucleotides are chiral at phosphorous, and those exhibiting
the Sp configuration are significantly more resistant to nucleases found in human plasma
than P-diastereomeric or Rp-phosphorothioated oligonucleotides. Methods for the syn-
thesis of oligonucleotides with stereodefined phosphorothioate linkages would therefore
be valuable in the preparation of therapeutic oligonucleotides with optimal resistance to Synthesis of
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nucleases. UNIT 4.17 specifically describes the use of deoxyribonucleoside-3′-O-(2-thio-
1,3,2-oxathiaphospholane) derivatives in the P-stereocontrolled synthesis of phospho-
rothioated oligonucleotides.
Another class of modified oligonucleotides with potential biomedical applications relates
to phosphorothiated oligodeoxyribonucleotides expressing specific CpG motifs. These
oligonucleotides strongly stimulate B cells, natural killers cells, and antigen-presenting
cells to proliferate and/or secrete cytokines, chemokines, and immunoglobulins. Given
that a number of structural factors influences the recognition of CpG-oligonucleotides
and expression of their immunostimulatory properties, UNIT 4.16 provides an overview
of the chemical strategies used to assess the significance of these factors toward the
development of human therapies.
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